Research

Hormonal

The peptide drug GUB021794, a GLP-1 receptor agonist derived from a secretin backbone, promotes dose-dependent body weight loss in diet-induced obese mice comparable to the clinically approved drug semaglutide.

This research identifies a new peptide drug, GUB021794, which mimics the hormone GLP-1 to reduce appetite and body weight. In obese mice, it worked as well as the popular drug semaglutide but was designed to last longer in the body, allowing for once-weekly dosing instead of daily. This suggests a potential future treatment option for obesity that offers similar weight loss benefits with less frequent administration.

GoodSupportsHIGH confidence
28-day treatment with GUB021794 promoted a dose-dependent reduction in body weight, on par with an equimolar dose (10 nmol/kg) of semaglutide (Figure 7A, B).
Jens Nielsen et al. · Journal of Medicinal Chemistry · 2024

Why this rating

The evidence is from a controlled animal study (DIO mice) with clear statistical significance (P < 0.05) and comparison to a gold-standard drug, though it is preclinical.

Source

Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties

Jens Nielsen et al. · Journal of Medicinal Chemistry · 2024

DOI 10.1021/acs.jmedchem.4c00417

mechanism_only · n=10Cited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →